Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200-Day Moving Average - Time to Sell?

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $13.61 and traded as high as $19.00. Assembly Biosciences shares last traded at $18.96, with a volume of 17,344 shares traded.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Wall Street Zen downgraded Assembly Biosciences from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a research note on Monday, March 24th. Finally, Guggenheim started coverage on Assembly Biosciences in a research note on Tuesday, March 25th. They issued a "buy" rating and a $31.00 price target on the stock.

Assembly Biosciences Price Performance

The stock has a market capitalization of $142.72 million, a PE ratio of -3.00 and a beta of 0.62. The business has a 50 day moving average price of $16.14 and a 200 day moving average price of $13.63.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.01) by $0.84. The firm had revenue of $9.42 million for the quarter, compared to the consensus estimate of $7.41 million. Assembly Biosciences had a negative return on equity of 131.77% and a negative net margin of 124.15%. On average, equities analysts expect that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Palumbo Wealth Management LLC increased its position in Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 681 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 6,823 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Assembly Biosciences during the 1st quarter valued at about $113,000. Man Group plc purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $309,000. Finally, B Group Inc. purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $799,000. Institutional investors own 19.92% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.